4/A: Director John Bakewell Amends XTNT Stock Ownership Filing

Xtant Medical Holdings director John K. Bakewell filed an amended Form 4 to correct his beneficial ownership, disclosing a new deferred stock unit award.

Summary

• John K. Bakewell, a Director of Xtant Medical Holdings, Inc. (XTNT), filed an amended Form 4 (Form 4/A) on November 18, 2025.
• The primary purpose of this amendment is to correct the number of shares beneficially held in column 5 of the original filing.
• On November 15, 2025, Bakewell was granted 158,228 deferred stock units (DSUs) under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, with a grant price of $0.
• These DSUs are scheduled to vest on November 15, 2026, contingent upon Bakewell remaining a director of Xtant through that date.
• The settlement of these vested shares will be deferred to a later date as per the DSU award agreement.
• Following this reported transaction and correction, Bakewell beneficially owns a total of 914,116 shares of common stock.
• This total beneficial ownership includes 465,570 shares issuable upon settlement of various DSU awards, conditioned on remaining a director through their respective vesting dates.

Sentiment

Score: 6

Explanation: The filing is largely neutral, detailing a routine insider compensation grant and an administrative correction. The grant itself is a positive for aligning director interests, but the need for an amendment is a minor negative.

Positives

• The grant of 158,228 deferred stock units to a director aligns management's long-term interests with those of shareholders.
• The company is actively utilizing its Amended and Restated 2023 Equity Incentive Plan to incentivize key personnel.

Negatives

• The necessity of filing an amendment to correct beneficial ownership suggests a potential administrative error in the initial disclosure.

Risks

• The vesting of the 158,228 deferred stock units is conditioned upon the reporting person remaining a director of Xtant Medical Holdings, Inc. through November 15, 2026.

Future Outlook

The grant of deferred stock units with a future vesting date suggests an expectation for the director to remain with the company for at least another year, reinforcing long-term alignment of interests.

Industry Context

This filing represents a routine insider transaction related to director compensation, which is a standard practice across publicly traded companies to incentivize leadership through equity-based plans. It does not provide broader insights into industry trends or competitive landscape.

Comparison to Industry Standards

• The grant of deferred stock units to a director is a common form of equity compensation in publicly traded companies, aligning director incentives with shareholder value creation.
• The specific size of the DSU grant would typically be benchmarked against peer companies of similar market capitalization and industry, though this filing does not provide such comparative data.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of DSUs to a director aligns their interests with shareholders, potentially encouraging long-term value creation. The correction in beneficial ownership provides accurate disclosure.

Next Steps

• The 158,228 deferred stock units are scheduled to vest on November 15, 2026.
• Settlement of the vested shares underlying the DSU award will occur at a later date pursuant to the terms of the DSU award agreement.

Key Dates

Recommendation

This filing primarily details a routine grant of deferred stock units to a director and an administrative correction to beneficial ownership. While the DSU grant aligns director incentives with shareholder interests, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Xtant Medical Holdings, XTNT, Form 4/A, Insider Trading, Beneficial Ownership, Deferred Stock Units, DSU, Equity Incentive Plan, Director Compensation, SEC Filing